SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cancer - Side effect drugs

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: John McCarthy who started this subject11/24/2002 6:19:05 PM
From: John McCarthy   of 57
 
2002 - [NSC12983]

: Anticancer Drug Des 2001 Apr-Jun;16(2-3):129-33 Related Articles, Links

Identification of a novel steroid derivative, NSC12983, as a paclitaxel-like tubulin assembly promoter by 3-D virtual screening.

Wu JH, Batist G, Zamir LO.

Human Health Research Center, INRS Institut Armand-Frappier, Universite du Quebec, Laval, Canada.

By flexibly docking 9593 compounds of the NCI-3D database against the refined structure of beta-tubulin using DOCK 4.0, a long-forgotten synthetic steroid derivative, NSC12983, has been identified as a microtubule-stabilizing agent. The 32 top scorers includes NSC12983 and the three added references: paclitaxel, docetaxel and IDN5109. That is, 12.5% of the 0.33% top scorers are active. In addition, NSC12983 is active on Mycobacterium tuberculosis in vitro and in vivo, which might be due to its ability to promote the assembly of essential cell division protein.

PMID: 11962510 [PubMed - indexed for MEDLINE]

ncbi.nlm.nih.gov
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext